title: Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
abstract: OBJECTIVE
  The European Schizophrenia Out-patient Health Outcomes study is an observational study investigating treatment in schizophrenia. We report treatment-emergent adverse events during the first 6 months of treatment.
  
  
  METHODS
  The rate of extrapyramidal symptoms (EPS), anticholinergic use, weight gain and sexual related dysfunctions were assessed in 8,400 out-patients.
  
  
  RESULTS
  Patients typical antipsychotics and risperidone experienced significantly more EPS and anticholinergic use than patients in the clozapine, olanzapine, and quetiapine cohorts. Patients treated with amisulpride, typical antipsychotics and risperidone were significantly more likely to have sexual related dysfunctions and/or amenorrhea. Increases in weight and body mass index occurred in all cohorts, but were significantly greater in the olanzapine and clozapine cohorts.
  
  
  CONCLUSIONS
  Patients treated with olanzapine, quetiapine and clozapine had better tolerability outcomes regarding EPS and sexual related dysfunctions compared with patients receiving risperidone, amisulpride and typicals. Patients treated with olanzapine and clozapine had higher weight increases than patients treated with risperidone, quetiapine and typicals.
authors.affiliation: Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg, Germany. lambert@uke.uni-hamburg.de
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: J M
authors.initials: JM
authors.lastname: Haro
authors.forename: D
authors.initials: D
authors.lastname: Novick
authors.forename: E T
authors.initials: ET
authors.lastname: Edgell
authors.forename: L
authors.initials: L
authors.lastname: Kennedy
authors.forename: M
authors.initials: M
authors.lastname: Ratcliffe
authors.forename: D
authors.initials: D
authors.lastname: Naber
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D000568:Amenorrhea / Q000139:chemically induced / Q000453:epidemiology; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced / Q000453:epidemiology; D006177:Gynecomastia / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008297:Male; D019370:Observation; D000077152:Olanzapine; D017063:Outcome Assessment, Health Care; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine